Role of Therapeutic Drug Monitoring and Challenges in the Management of Infantile Chronic Myeloid Leukemia
Sneha Tandon1, Raviraj Deshpande2, Gaurav Narula3, Maya Prasad3, Amey Paradkar3, Vikram Gota2, S. D. Banavali3.
1Division of Pediatric Hematology Oncology, Department of Pediatrics, University Hospital Southampton, United Kingdom,
2Department of Clinical Pharmacology, ACTREC, Mumbai, India,
3Department of Pediatric Oncology, Tata Memorial Centre, Mumbai, India.
Abstract
Chronic myeloid leukemia (CML) is a rare pediatric cancer, more so in children below four years of age. Treating infants with CML can be challenging especially with ensuring compliance to therapy. We report two infants with adult type CML and the role of therapeutic drug monitoring (TDM) during tyrosine kinase inhibitor therapy (TKI) therapy in their treatment.

READ FULL TEXT
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0